
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
From Adoption to Governance in Radiology: Navigating the Next Wave of Imaging AI
2
Observations and Reflections from the 2026 SNMMI Conference: An Interview with Jeremie Calais, MD, PhD
3
Study Shows 45 Percent Increase in Emergency Department Neuroimaging Over the Last Decade
4
FDA Clears Emerging AI Segmentation Module for Brain MRI
5












